BioCentury
ARTICLE | Emerging Company Profile

Building Resilience into U.S. biomanufacturing

With more than $800M in cash, Resilience aims to streamline manufacturing services spanning preclinical development through commercialization

November 25, 2020 1:22 AM UTC

In addition to building manufacturing infrastructure across multiple modalities, Resilience plans to offer its clients standardized protocols and consulting services that could help cut down on production wait and lead times as well as CMC issues. 

The company debuted Monday with over $800 million from two financings, including a $750 million series B led by Arch Venture Partners and 8VC. Also participating were GV, NEA, and undisclosed investors including public mutual funds, large U.S.-based pharmas, foundations, family offices and pension funds...

BCIQ Company Profiles

Agios Pharmaceuticals Inc.